Skip to content
LaunchIndex
Browse/2026/11/aeonvital.bio

循生医学 AeonVital · TIL 细胞治疗与治疗性核酸疫苗

aeonvital.bio

LaunchIndex first observed 循生医学 AeonVital · TIL 细胞治疗与治疗性核酸疫苗 (aeonvital.bio) live on 12 November 2026. View its launch screenshot, category, technologies, and verification evidence.

Visit aeonvital.bio External site · Last checked November 12, 2026
Screenshot of aeonvital.bio
Captured November 12, 2026 10:44 as part of the recorded launch evidence.
Observed launch story

A launch record built from evidence.

循生医学 AeonVital · TIL 细胞治疗与治疗性核酸疫苗 (aeonvital.bio) was first observed live on 12 November 2026.

Biotech company focused on tumor immunotherapy using tumor-infiltrating lymphocytes and therapeutic nucleic acid vaccines (DNA/mRNA) for solid tumors and HPV-related diseases, with pipelines like ReT01 ACT and AVL-101/AVL-102.

Its profile is classified as Professional service within Health / Health and wellness. Verification detected Next.js.

Recorded evidence

What the launch signal contained.

First observed live
Previous state
No prior non-live observation
Last verified
Canonical host
www.aeonvital.bio
Category
Health / Health and wellness
Website type
Professional service
Observed title
循生医学 AeonVital · TIL 细胞治疗与治疗性核酸疫苗
Observed description
北京循生生物医学研究有限公司(循生医学 / 循生生物)成立于 2021 年,是一家以细胞及基因治疗为核心的创新生物医药公司,专注于肿瘤浸润淋巴细胞(TIL)创新疗法与核酸药物(DNA 和 mRNA)开发。
Detected technologies
Next.js
Screenshot captured
Evidence source
Browser observation · Local
Evidence confidence
93%
HTTP status
200
Share this record

A canonical launch profile for aeonvital.bio.

Share the profile directly or add the optional badge to the website. A badge is never required for inclusion, verification, or ranking.

Share profile
Website owner

Is this your website?

Claim this profile to add verified owner information.

Claim website
Community signal

What do you make of this launch?

Vote on the site and leave a short note for other people exploring the new web.

↑0Up
↓0Down

Join the discussion

Sign in with Google to vote or comment.

Sign in to participate

Comments

0 comments
No comments yet

Be the first to leave a useful observation.

Report an issueFlag spam, illegal or harmful content, or inaccurate information.

Reports are private and reviewed by the moderation team. No sign-in is required, so this report will be anonymous.

Private to moderators · 10–2,000 characters